PMID- 22404486
OWN - NLM
STAT- MEDLINE
DCOM- 20141020
LR  - 20140807
IS  - 1365-2036 (Electronic)
IS  - 0269-2813 (Linking)
VI  - 35
IP  - 9
DP  - 2012 May
TI  - High-dose rabeprazole-amoxicillin dual therapy and rabeprazole triple therapy 
      with amoxicillin and levofloxacin for 2 weeks as first and second line rescue 
      therapies for Helicobacter pylori treatment failures.
PG  - 1097-102
LID - 10.1111/j.1365-2036.2012.05054.x [doi]
AB  - BACKGROUND: H. pylori eradication failures are difficult to treat and rescue 
      therapies often consist of complex treatment regimens. AIM: To determine an 
      effective and practical rescue therapeutic strategy for H. pylori treatment 
      failures using two consecutive regimens: first rescue therapy - rabeprazole 20 mg 
      t.d.s. and amoxicillin 1 g t.d.s. for 2 weeks and for failures a further second 
      rescue therapy - rabeprazole 20 mg b.d., levofloxacin 500 mg b.d., amoxicillin 1 
      g b.d. for a further 2 weeks. METHODS: Consecutive patients who failed the proton 
      pump inhibitor (PPI) 1-week triple therapy were recruited for the study. H. 
      pylori status was determined by a C(13) urea breath test. RESULTS: One hundred 
      and forty-nine patients received the first rescue therapy. Seven were not 
      compliant to medication/defaulted follow-up. Eradication success- first rescue 
      therapy: per protocol (PP) analysis-107/142 (75.4%) (95% CI (68.3-82.4%) and 
      intention to treat (ITT) analysis-107/149 (71.8%) 95% CI (64.6-79.0%). Thirty-one 
      of 35 patients who failed the first rescue therapy received the second rescue 
      therapy. All were compliant with medications. Eradication success- PP and ITT was 
      28/31 (90.3%) 95% CI (74.2-98.0%). The cumulative eradication rate using both 
      rescue therapies: PP analysis- 135/138 (97.8%) 95% CI: (93.8-99.6%), ITT 
      analysis- 135/149 (90.6%) 95% CI: (84.7-94.8%). CONCLUSIONS: A 2-week high dose 
      PPI-amoxicillin dual therapy followed by a PPI-amoxicillin-levofloxacin triple 
      therapy were highly successful in achieving eradication in H. pylori treatment 
      failures.
CI  - (c) 2012 Blackwell Publishing Ltd.
FAU - Goh, K-L
AU  - Goh KL
AD  - Division of Gastroenterology and Hepatology, University of Malaya, Kuala Lumpur, 
      Malaysia.
FAU - Manikam, J
AU  - Manikam J
FAU - Qua, C-S
AU  - Qua CS
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120308
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - 32828355LL (Rabeprazole)
RN  - 6GNT3Y5LMF (Levofloxacin)
RN  - 804826J2HU (Amoxicillin)
RN  - 8W8T17847W (Urea)
SB  - IM
MH  - Amoxicillin/administration & dosage/therapeutic use
MH  - Anti-Bacterial Agents/administration & dosage/*therapeutic use
MH  - Breath Tests
MH  - Drug Therapy, Combination
MH  - Follow-Up Studies
MH  - Helicobacter Infections/*drug therapy/microbiology
MH  - Helicobacter pylori/*drug effects/isolation & purification
MH  - Humans
MH  - Levofloxacin/administration & dosage/therapeutic use
MH  - Prospective Studies
MH  - Proton Pump Inhibitors/administration & dosage/*therapeutic use
MH  - Rabeprazole/administration & dosage/therapeutic use
MH  - Treatment Failure
MH  - Treatment Outcome
MH  - Urea/metabolism/pharmacology
EDAT- 2012/03/13 06:00
MHDA- 2014/10/21 06:00
CRDT- 2012/03/13 06:00
PHST- 2011/12/25 00:00 [received]
PHST- 2012/01/25 00:00 [revised]
PHST- 2012/02/19 00:00 [revised]
PHST- 2012/02/20 00:00 [accepted]
PHST- 2012/03/13 06:00 [entrez]
PHST- 2012/03/13 06:00 [pubmed]
PHST- 2014/10/21 06:00 [medline]
AID - 10.1111/j.1365-2036.2012.05054.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2012 May;35(9):1097-102. doi: 
      10.1111/j.1365-2036.2012.05054.x. Epub 2012 Mar 8.